Preliminary results of hepatitis B vaccination (HEVAC B) in healthy subjects and haemodialysis patients.
Hepatitis B vaccine (Hevac B, Pasteur) was assessed in 52 healthy and 25 haemodialysis individuals. The percentage of hepatitis B surface antibody seroconversion was 100% in the first group but only 57.7% in the other one. The mean levels of hepatitis B surface antibody, 3 months after the first injection were respectively 222 and 42 milli International Units per ml. Five health-care workers, who experienced an accidental exposure were protected by a combined passive-active immunization.
D000328:Adult; D000917:Antibody Formation; D005260:Female; D006510:Hepatitis B Antibodies / Q000032:analysis; D017325:Hepatitis B Vaccines; D006801:Humans; D008297:Male; D006435:Renal Dialysis; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology*
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014765:Viral Vaccines